BabyCue

Disposable Paper-Based Diarrhea Diagnostic Kit Integrated with GI-Bud for Rapid Detection and Child Digestive Health Monitoring

Rapid and accurate diarrhea detection using DiaCue in 10-15 minutes

Non-invasive sampling using the innovative GI-Bud

Trusted results to guide informed medical decisions

AI-powered mobile app for remote monitoring and personalized care

About Us

Babycue Private Limited, a healthcare start-up founded in 2021 and incubated at Yenepoya Technology Incubator (YTI), is dedicated to advancing cost-effective, point-of-care diagnostics. At Babycue, we are developing an innovative microfluidic paper-based testing platform utilizing the lateral flow assay (LFA) approach to enable the early detection and differentiation of diarrheal infections. This platform is designed to distinguish bacterial from viral infections by analyzing specific biomarkers, enhancing diagnostic accuracy at the point of care.

Services

Childhood diarrhea is the second leading cause of morbidity and mortality among children, despite the availability of effective treatments. Lack of early point-of-care diagnostic tools prevents timely and accurate differentiation of diarrheal infections, hindering clinical decision-making. An urgent need exists for an early diagnostic tool that can distinguish bacterial from viral diarrhea, supporting more precise treatment and reducing the strain on healthcare systems. This limitation contributes to: